Two “parallel threats” to modern antibiotics have been highlighted by Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball, in the form of both antimicrobial resistance and the “increasing dysfunctionality” of the market framework for existing treatments.
Sandoz Pushes Back On AMR And ‘Dysfunctional’ Antibiotics Market
Get Access Balance Right And Consider Market Reforms, Urge Senior Executives
Sandoz CEO Richard Saynor and global head of anti-infectives Ian Ball have spoken out on the threat of antimicrobial resistance and the “increasing dysfunctionality” of the market framework for antibiotics.
More from Generics
• By
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.